Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan 10;29(3):451-8.
doi: 10.1016/j.vaccine.2010.10.076. Epub 2010 Nov 12.

"Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination

Affiliations

"Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination

P A Newman et al. Vaccine. .

Abstract

The Step Study phase IIb HIV-1 vaccine trial was terminated early due to futility; subsequent analyses revealed increased susceptibility to HIV infection among a subset of test vaccine recipients. We conducted a mixed methods investigation, including a brief, self-administered baseline questionnaire and in-depth, semi-structured, 1-h interviews after unblinding, to explore experiences and perspectives among trial participants and key informants. Interviews were digitally recorded, transcribed, and analyzed using NVivo and thematic techniques. Forty-eight trial participants (46 gay/bisexual men) completed baseline surveys; 15 (14 gay/bisexual men) engaged in post-trial interviews. Participants indicated surprise and disappointment about the early trial termination and unexpected risks. Some articulated understanding the uncertainties of clinical trials, steadfast support and willingness to participate in the future; others reported greater risks than they deemed acceptable and unlikelihood of volunteering again. A few indicated mistrust of trial sponsors and ethics. Participants' most profound criticism was not about unexpected results, but perceived delays in unblinding and gaps in post-trial dissemination of information. Future HIV vaccine trials may benefit from increased emphasis on: (1) communication mechanisms among participants, investigators and trial sponsors, and (2) post-trial dissemination of information and psychosocial support.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. N Engl J Med. 2009;23(361):2209–2220. - PubMed
    1. Michael N. RV 144 Update: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thai Adults; 17th Conference on Retroviruses and Opportunistic Infections (CROI): Abstract 74. Presented February 18, 2010; http://retroconference.org/2010/Abstracts/39837.htm.
    1. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613–619. - PMC - PubMed
    1. Dolin R. HIV vaccine trial results--an opening for further research. N Engl J Med. 2009;361(23):2279–2280. - PubMed
    1. Newman PA, Daley A, Halpenny R, Loutfy M. Community heroes or ‘high-risk’ pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine. 2008;26(8):1091–1097. - PubMed

Publication types